Buysiders say a steady flow of positive news could play a critical role in reinvigorating investor interest in biotech, and are especially watchful for news from Gilead Sciences Inc., Vertex Pharmaceuticals Inc. and companies presenting at the American Society of Clinical Oncology meeting in June.

Among the large caps, some fund managers see the March pullback as an attractive buying opportunity, particularly if the sell-off persists.